Compare British American Tobacco PLC (BTI) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Heron Therapeutics Inc — how do they compare? British American Tobacco PLC trades at $55.9 (market cap $122.36B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: British American Tobacco PLC is far larger — about 1990.6× Heron Therapeutics Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BTI | HRTX | |
|---|---|---|
Market Cap | $122.36B | $61.47M |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $1.49 |
52-Week Low | $50.39 | $0.32 |
Enterprise Value | $166.31B | $168.21M |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.9, down 2.02% today, with a bearish technical signal overall despite bullish oscillators. The company reported Q2 2026 EPS of $2.25, beating expectations, and maintains strong profitability with a 24.99% net income margin. Recent news highlights its strategic tech partnership with ITC Infotech and workforce restructuring to cut costs.
Outlook is mixed: strong fundamentals and a 66.67% analyst buy rating support upside, but technical weakness and regulatory risks pose challenges. The stock offers value with a P/E of 14.48 and dividend yield, yet faces headwinds from declining combustibles and debt levels.
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
